New Disease Progression Research Reported from Proteogenomics Research Institute for Systems Medicine (Insights into Disease Progression of Translational Preclinical Rat Model of Interstitial Pulmonary Fibrosis through Endpoint Analysis).

Researchers at the Proteogenomics Research Institute for Systems Medicine have conducted a study on the disease progression of interstitial pulmonary fibrosis (IPF) using a rat model. The study focused on the effect of different concentrations of bleomycin, a drug used to induce lung fibrosis, on disease progression. The researchers found that a single bleomycin challenge resulted in progressive fibrosis in the rat lung tissue over 14 days, with different signaling pathways and proteins involved at different stages of the disease. The study provides valuable insights for understanding IPF and developing potential therapeutic interventions. [Extracted from the article]

Copyright of Respiratory Therapeutics Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)